Spero Therapeutics board changes: Vink resigns, Ho appointed as Class II director
Patrick Vink stepped down from Spero's board effective November 10, 2026, and William Ho was appointed to fill the vacancy the same day.
Spero Therapeutics disclosed in an 8-K that Patrick Vink, M.D., a Class II director, notified the board on November 9, 2026 of his decision to resign his seat, along with his posts as chair of the Nominating and Corporate Governance Committee and member of the Compensation Committee, and from any subsidiary board roles, effective November 10, 2026.1 The company stated that Vink's resignation did not stem from any dispute with the company, its management, or other board members over operations, policies, or practices.1 Spero also noted Vink had served the company for 11 years.1
The board, acting on the recommendation of its Nominating and Corporate Governance Committee, appointed William Ho, M.D., Ph.D., as a Class II director to fill Vink's vacancy, also effective November 10, 2026.1 Ho was additionally named to the board's Development Committee.
According to the filing, Ho has over 20 years of clinical development experience spanning oncology, allergy, and immunology.1 He most recently served as Chief Medical Officer of RAPT Therapeutics from 2015 to December 2025, where he oversaw U.S. and ex-China development plans and launched clinical work on an in-licensed, next-generation anti-IgE antibody program.1 The filing added that this program contributed to GSK's $2.2 billion acquisition of RAPT Therapeutics, which closed in March 2026.1 Earlier in his career, he held posts at Igenica Biotherapeutics leading antibody-based therapeutics development, and spent seven years at Genentech's Research and Early Development group in BioOncology, guiding small-molecule, antibody, and antibody-drug conjugate programs from IND filing through Phase 3.1
Under his new role, Ho will receive an annual cash retainer of $40,000 for board service plus $5,000 for Development Committee membership, and was granted an option for 100,000 shares vesting monthly over one year.1 The filing states there are no arrangements tied to his selection, no related-party transactions under Item 404(a), and no family ties to existing directors or officers.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.